Cost-effectiveness of influenza vaccination in the Netherlands;Kosteneffectiviteit van influenzavaccinatie in Nederland

Nederlands Tijdschrift voor Geneeskunde

Volumn 141, Issue 2, 1997, Pages 93-97

  Reinders, A ^a   Postma, M J ^a   Govaert, Th M E ^a   Sprenger, M J W ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

AGE; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; INFLUENZA; NETHERLANDS; VACCINATION;

ADULT; AGED; COST-BENEFIT ANALYSIS; EPIDEMIOLOGIC METHODS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, ECONOMIC; NETHERLANDS; VACCINATION; VALUE OF LIFE;

EID: 0031032003     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sprenger MJW, Mulder PG, Beyer WE, Strik R van, Masurel N. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993;522: 334-40.
2. Schoenbaum SC. Economic impact of influenza. The individual's perspective. Am J Med 1987;82:26-30.
3. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993;153:2105-11.
4. Gross PA, Hermogenes AW, Sacks US, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
5. Sprenger MJW, Desmyter J, Masurel N. Minderheidsstandpunt over influenzavaccinatie bij ouderen. Ned Tijdschr Geneeskd 1991;135:2208-10.
6. Jefferson T, Mugford M, Gray A, Demicheli V. An exercise on the feasibility of carrying out secondary economic analysis. Health Econ 1996;5:155-65.
7. Office of Technology Assessment: US Congress. Cost-effectiveness of influenza vaccination. Washington: Government Printing Office, 1981.
8. Fedson DS, Hannoun C, Leese J, Sprenger MJ, Hampson AW, Bro-Jorgensen K, et al. Influenza vaccination in 18 developed countries, 1980-1992. Vaccine 1995;13:623-7.
9. Reinders A, Postma MJ, Sprenger MJ W. Kosteneffectiviteitsanalyse van vaccinatie legen influenza in Nederland. RIVM-rapport nr 431501007. Bilthoven: RIVM, 1996.
10. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333:889-93.
11. Ruwaard D, Kramers PGN, redacteuren. Volksgezondheid Toekomst Verkenning. Den Haag: SDU, 1993.
12. Genugten MLL van, Rutten FFH, Jager JC. Scenario development and costing in health care. Utrecht: International Books, 1996.
13. Drummond MF, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good?. Soc Sci Med 1993;37:33-40.
14. Koopmanschap MA, Roijen L van, Bonneux L, Barendregt JJ. Indirect costs in economic studies: confronting the confusion. PharmacoEcon 1993;6:446-54.
15. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
16. Lombaert G. Vaccinatie legen griep: een economische evaluatiestudie voor België. Informatiebulletin Vereniging voor Gezondheidseconomie 1996;13:8-10.
17. Sprenger MJW, Beyer WEP, Ament AJHA, Rutten FFH, Masurel N. Influenza-vaccinatie leidt tot kostenbesparing in de gezondheidszorg. TSG 1987;65:222-5.
18. Martens LL. De kosten-effectiviteit van screening van zwangeren op hepatitis B. TSG 1989;67:379-82.
19. Gruteke P, Postma MJ, Grosheide PM, Jager JC, Conyn-van Spaendonck MAE, Loeber JG. Preventie van congenitale syfilis. RIVM-rapport nr 199003042. Bilthoven: RIVM, 1995.
20. Koopmanschap NIA, Lubbe KT, Oortmarssen GJ van, Agt HM van, Ballegooijen M van, Habbema JK. Economic aspects of cervical cancer screening. Soc Sci Med 1990;30:1081-7.
21. De Charro FTh, Bonsel GJ. Hout BA van. De kosten en effecten van harttransplantatie. Rotterdam: Instituut voor Maatschappelijke Gezondheidszorg, Erasmus Universiteit Rotterdam, 1988.